within Pharmacolibrary.Drugs.ATC.L;

model L01EJ01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.00031666666666666665,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 15.0,            
    Vdp             = 0.183,
    k12             = 36.1,
    k21             = 36.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EJ01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ruxolitinib is a selective Janus kinase (JAK1 and JAK2) inhibitor indicated for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It is an oral medication approved and used clinically to manage these hematological conditions.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model developed for adult patients with myelofibrosis, based on data from healthy subjects and patients (males and females, adults, age range ~18–80 years).</p><h4>References</h4><ol><li><p>Persaud, I, et al., &amp; Yeleswaram, S (2020). Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. <i>International journal of pharmaceutics</i> 590 119889–None. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2020.119889\">10.1016/j.ijpharm.2020.119889</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32949620/\">https://pubmed.ncbi.nlm.nih.gov/32949620</a></p></li><li><p>Cook, E, et al., &amp; Khandelwal, P (2024). Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease. <i>Transplantation and cellular therapy</i> 30(5) 528.e1–528.e12. DOI:<a href=\"https://doi.org/10.1016/j.jtct.2024.02.018\">10.1016/j.jtct.2024.02.018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38401793/\">https://pubmed.ncbi.nlm.nih.gov/38401793</a></p></li><li><p>Locatelli, F, et al., &amp; Diaz-de-Heredia, C (2024). Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. <i>The Lancet. Haematology</i> 11(8) e580–e592. DOI:<a href=\"https://doi.org/10.1016/S2352-3026(24)00174-1\">10.1016/S2352-3026(24)00174-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39002551/\">https://pubmed.ncbi.nlm.nih.gov/39002551</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EJ01;
